AI city halls: could Robot-Run domes cure addiction and homelessness?

NCT ID NCT07661823

First seen Jun 26, 2026 · Last updated Aug 13, 2026 · Updated 7 times

Summary

This study will test whether living in a self-contained, AI-managed community (called a Microcity) can improve mental health and reduce addiction in adults with conditions like autism, ADHD, substance use disorders, and behavioral addictions. Up to 1 million participants will live in a dome-enclosed village for up to 24 months, receiving AI-driven counseling, virtual reality therapy, and other digital treatments. The goal is to see if this approach can lower costs and improve outcomes for people on fixed incomes or public assistance.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
AI-managed community with behavioral health services (AI counseling, VR therapy, attitude inoculation protocols)
What this could lead to
If it works, this could point toward a new, low-cost way to deliver mental health and addiction care using AI and self-contained communities.
What could go wrong
This is a very early, non-randomized study with no FDA-regulated drugs or devices. The approach is highly experimental, and results may not apply to broader populations. The massive enrollment goal (1 million) and complex AI system may face practical challenges.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ABSTINENCE, SEX are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Administrative Office

    Richmond, Virginia, 23219, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.